Category: Derma Sciences Inc.
Derma Sciences raises $36 million closes a $36 million public stock offering it plans to use to continue development on its lead drug candidate for diabetic foot ulcers.
Derma Sciences (NSDQ:DSCI) said it's closed an offering of some 3.5 million shares of its stock at $10.34 apiece.
The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.
Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.
Derma Sciences president & CEO Edward Quilty resigns from the company's board of directors after Nasdaq's listing qualifications officers noted that his membership was in violation of listing rules.
Derma Sciences (NSDQ:DSCI) president & CEO Edward Quilty resigned from the company's board of directors, settling a non-compliance issue that could have led to delisting from the Nasdaq stock exchange.
Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax.
Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.
Intuitive Surgical, fresh off of an all-time high of $554.13 per share, could once again blindside analysts on The Street with its quarterly earnings results; also, NeuroLogica inks another joint development deal; Air Force taps LongView CIO for $985M medical services contract; Henry Schein wins DoD contract extension; plus, a Funding Roundup and analysts' ups and downs.
A week after posting an all-time stock high, Intuitive Surgical (NSDQ:ISRG) is poised to bedazzle Wall Street for the 12th straight quarter tomorrow.
Boston Scientific launches its BackStop kidney stone treatment, licensed from Pluromed, in the U.S. and certain international markets; also, Siemens lands 3rd year defense contract worth up to $1.9 billion; Bruker Corp. nabs all shares of SkyScan for an undisclosed amount; Viking expects 40% sales growth for Q1 2012; Smith & Nephew acquires LifeModeler for an undisclosed amount; Wound Care Innovations signs exclusive N.A.
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
